Mersana Therapeutics Inc (MRSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.19 Million) by net assets ($-59.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Mersana Therapeutics Inc to measure how much of total assets are equity-financed.
Mersana Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MRSN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Mersana Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mersana Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trada Maritime Tbk
JK:TRAM
|
0.009x |
|
Tavia Acquisition Corp. Unit
NASDAQ:TAVIU
|
-0.001x |
|
Molecular Partners AG
SW:MOLN
|
-0.099x |
|
Cegedim S.A.
PA:CGM
|
0.260x |
|
GeoVision Inc
TW:3356
|
-0.025x |
|
Gevelot
PA:ALGEV
|
0.039x |
|
Paragon Globe Bhd
KLSE:3611
|
-0.008x |
|
Smart Gunes Enerjisi Teknolojileri Arastirma Gelistirme Uretim Sanayi ve Ticaret
IS:SMRTG
|
0.134x |
Annual Cash Flow Conversion Efficiency for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Mersana Therapeutics Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Mersana Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-9.51 Million | $-82.34 Million | 8.659x | +289.22% |
| 2023-12-31 | $36.90 Million | $-168.88 Million | -4.576x | -753.42% |
| 2022-12-31 | $92.06 Million | $-49.36 Million | -0.536x | +53.37% |
| 2021-12-31 | $121.74 Million | $-139.99 Million | -1.150x | -251.12% |
| 2020-12-31 | $228.09 Million | $-74.70 Million | -0.327x | +62.14% |
| 2019-12-31 | $78.32 Million | $-67.74 Million | -0.865x | +86.22% |
| 2018-12-31 | $8.79 Million | $-55.22 Million | -6.278x | -929.62% |
| 2017-12-31 | $69.99 Million | $-42.68 Million | -0.610x | -7.36% |
| 2016-12-31 | $-55.62 Million | $31.59 Million | -0.568x | -351.62% |
| 2015-12-31 | $-42.69 Million | $-9.64 Million | 0.226x | -- |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more